Amit B. Agarwal

Hematology
1 Gustave L Levy Pl
New York, NY 10029

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications

Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 18, 2013
Showing 1-1 of 1

Last Updated: 09/26/2026